Fennec Pharmaceut…
USUSDFennec Pharmaceuticals Inc (TO:FRX) — Biotechnology: Biological Products (No Diagnostic Substances). Кількість бірж, де торгуються акції компанії: 2. На сторінці — ціна й графік, дивіденди, найбільші власники та історія кількості акцій.
Про компанію
- Сайт
- fennecpharma.com
- Для інвесторів
- investors.fennecpharma.com/
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Штаб-квартира
- RESEARCH TRIANGLE PARK, United States
- Керівник
- Jeffrey S. Hackman
- Працівників
- 35
- На біржі з
- 12.06.2001 (TO:FRX)
- Акцій в обігу
- 35.07 млн на 2026-08-11
- Вільний обіг
- 19.88 млн
- Капіталізація
- 375.57 млн USD
- Інсайдери
- 14.13%
- Інституції
- 54.24%
- Галузь (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- збиток
- FCF
- 3.92 млн USD
- Борг
- 19.4 млн USDгрошей більше за борг
- Прибуток і FCF — за 12 місяців до 30.06.2026 (останній звіт компанії).
- NAV
Опис
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Найбільші власники
| Власник | Частка | Акцій | Дата звіту |
|---|---|---|---|
| Rosalind Advisors, Inc. | 9.07% | 3.19 млн | 2026-06-30 |
| AIGH Capital Management… | 7.07% | 2.49 млн | 2026-06-30 |
| Solas Capital Management… | 5.38% | 1.89 млн | 2026-06-30 |
| Blackrock Inc. | 4.92% | 1.73 млн | 2026-06-30 |
| AWM Investment Company,… | 3.3% | 1.16 млн | 2026-06-30 |
| Vanguard Capital Managem… | 2.39% | 839 306 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.32% | 815 192 | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.11% | 742 194 | 2026-08-31 |
| Prospect Capital Advisor… | 1.42% | 497 800 | 2026-06-30 |
| State Street Corporation | 1.21% | 426 004 | 2026-06-30 |
| Geode Capital Management… | 1.15% | 402 566 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.9% | 316 471 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.78% | 274 781 | 2026-08-31 |
| ANDRADE ROBERT C (Chief… | ≈0.69% | 241 306 | 2026-08-31 |
| Jane Street Group, LLC | 0.67% | 233 877 | 2026-06-30 |
| VANGUARD SCOTTSDALE FUND… | 0.42% | 149 156 | 2026-05-31 |
| RAYKOV ROSTISLAV CHRISTO… | ≈0.35% | 124 411 | 2026-09-01 |
| Bridgeway Funds, Inc.-Ul… | 0.31% | 108 005 | 2026-06-30 |
| iShares Trust-iShares Mi… | 0.28% | 98 294 | 2026-08-31 |
| College Retirement Equit… | 0.24% | 85 124 | 2026-06-30 |
| SCHWAB CAPITAL TRUST-Sch… | 0.2% | 70 504 | 2026-07-31 |
| HACKMAN JEFFREY S (Chief… | ≈0.19% | 67 461 | 2026-09-30 |
| RALLIS CHRISTOPHER ANIGE… | ≈0.18% | 63 077 | 2026-05-11 |
| Quantitative Master Seri… | 0.14% | 50 481 | 2026-06-30 |
| CIOFFI CHRISTIANA MARIE… | ≈0.07% | 24 644 | 2026-08-31 |
| EVANS TERRY L (Officer) | ≈0.06% | 21 687 | 2026-09-30 |
| SAYAD PIERRE SARGIS PH.D… | ≈0.03% | 9 687 | 2026-09-30 |
| BRUGHERA MARCO MARIA (Di… | — | 0 | 2026-09-15 |
| SOUTHPOINT CAPITAL ADVIS… | — | — | 2025-12-24 |
